Naveen Pemmaraju, MD
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy for which there are few treatment options outside of cytotoxic chemotherapy. A new investigational agent, SL-401 (tagraxofusp, Elzonris), may provide an effective targeted therapy for patients with BPDCN, according to Naveen Pemmaraju, MD.
Findings from a pivotal phase II trial presented at the 2018 European Hematology Association Congress showed that SL-401 was active in this patient population and had a manageable safety profile. Overall response rate (ORR) was 90% for patients treated with SL-401 as frontline therapy, reported Pemmaraju.
In August 2018, the FDA granted a priority review designation to a biologics license application (BLA) for SL-401 as a treatment for patients with BPDCN. The agency is scheduled to decide on the BLA by February 21, 2019.
... to read the full story